Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated April 3, 2024, it has closed a first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Offering") through the issuance of an additional 285,714 units (the "Units") at a price of $0.46 per Unit for additional gross proceeds of $131,428.

Awakn also announces Private Placement

Toronto, Ontario--(Newsfile Corp. - March 15, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for February 2024.

Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Awakn Life Sciences Corp., a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD").

Toronto, Ontario--(Newsfile Corp. - Le 9 février/February 2024) - The common shares of Awakn Life Sciences Corp. have been approved for listing on the CSE.

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has received approval to have the common shares ("Common Shares") of the Company listed on the Canadian Securities Exchange (the "CSE") under the symbol "AWKN" at the opening of markets on February 13, 2024. Further to the Company's press release dated November 10, 2023, the Company will no longer trade on Cboe Canada ("Cboe") effective close of trading on February 12, 2024. No action is required by shareholders in connection with this change of listing.

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce, further to its press release dated November 10, 2023, that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the "CSE") subject to fulfilling customary CSE requirements. The Company intends to delist its common shares from Cboe Canada and is working to ensure that trading of its common shares on the CSE will commence immediately following such delisting, with an effective date to be disclosed in due course. The Company's trading symbol "AWKN" will remain the same.

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market

Toronto, Ontario--(Newsfile Corp. - December 20, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing Medication-Assisted Treatments to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company. The agreement is for a proprietary S-ketamine formulation, administered sublingually via an oral thin film (OTF). Awakn will have global exclusivity of its use in the treatment of Addiction, Anxiety Disorders, and Eating Disorders.

Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), shares a corporate update on recent progress. Awakn also announces the closing of the fourth tranche of its previously announced private placement.

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder

Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received a notice (the "Notice") from Cboe Canada ("Cboe") indicating that Awakn is not in compliance with Section 3.01(3) of Cboe's Listing Manual. Awakn has 90 days to address the non-compliance.

Toronto, Ontario--(Newsfile Corp. - October 31, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has engaged Orphan Insight Ltd ("Orphan Insight") to develop and advance market access, pricing, and reimbursement for Awakn's lead program AWKN-P001. AWKN-P001 targets Severe Alcohol Use Disorder (SAUD), the most chronic type of AUD, a condition affecting approximately 17 million individuals in the United States and the key European markets of UK, Germany, France, Italy, and Spain.

Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric Absorption

Announces Closing of Third Tranche of Private Placement

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder

Sale Completes Awakn's Exit From Healthcare Services To Focus Solely on Biotechnology Research and Development

Licenses Awakn Kare and Certain Healthcare Intellectual Property Assets to New Owners

Toronto, Ontario--(Newsfile Corp. - June 27, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting") held earlier today.

Conference hosted by M-Vest, Awakn to present on Thursday, June 22nd at 9:00 A.M. ET

Toronto, Ontario--(Newsfile Corp. - June 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce the closing of the second tranche and upsizing of its previously announced non-brokered private placement financing.

TORONTO, June 9, 2023 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - June 9, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn") a biotechnology company developing therapeutics targeting addiction, with a near term focus on Alcohol Use Disorder, announces today its intention to exit healthcare services to focus solely on research and development ("R&D") of therapeutics to treat addiction and licensing of its intellectual property.

TORONTO, June 9, 2023 /CNW/ - The following issues have been halted by CIRO:

Annual Revenue Increased by 534%

TORONTO, April 26, 2023 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - April 26, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce a non-brokered private placement financing for gross proceeds of up to $3,000,000 through the issuance of up to 6,521,739 units in the capital of the Company (the "Units") at a price of $0.46 per Unit (the "Offering"), and that the Company has closed the first tranche of the Offering issuing 2,392,858 Units for gross proceeds of $1,100,715.

TORONTO, April 26, 2023 /CNW/ - The following issues have been halted by IIROC:

Phase III Trial Will Assess Ketamine-Assisted Therapy for the Treatment of Severe Alcohol Use Disorder

Toronto, Ontario--(Newsfile Corp. - April 12, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is today providing a corporate update.

Partnership is Awakn's first with a dedicated addiction treatment clinic, Ken Starr MD Wellness Group

Awakn Will License its Protocols for Treating Addiction and Mental Health to a Healthcare Consortium to Help Accelerate Their Development of a Chain of Clinics in Portugal

Awakn Clinics Trondheim is its second clinic in Norway

Toronto, Ontario--(Newsfile Corp. - February 9, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announced it has initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis® ODT fast dissolve technology.

Toronto, Ontario--(Newsfile Corp. - February 8, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that it has been requested by OTC Markets Group Inc. ("OTC Markets") to issue this statement about promotional activity concerning its common stock.

Designation Aims to Accelerate Time to Market

Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II

And continued successful execution of R&D and Commercialization strategies

Phase III trial confirmed to cost CA$3.75 million, with a UK Government agency funding 66% of this cost

Trondheim in central Norway will be the location of Awakn's 4th clinic

Awakn's Nordic expansion begins with new Awakn Clinics Oslo

Toronto, Ontario--(Newsfile Corp. - November 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated September 15, 2022, it has closed a second and final tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering") through the issuance of an additional 3,395,812 units (the "Units") at a price of $0.55 per Unit for additional gross proceeds of $1,867,697

Awakn will Partner with Nushama, One of New York's Leading Ketamine-assisted Therapy Centers

Awakn has raised approx. CAD$775K to grow its Nordic clinics business

Toronto, Ontario--(Newsfile Corp. - September 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended July 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars ("CAD"), unless otherwise specified.

Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces it has signed a drug development agreement with Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities.

Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine

Licensing Partnership with Wellbeings(R) marks entry into Canadian addiction treatment and relapse prevention market

REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’) to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention.

Awakn enters the U.S. addiction treatment and relapse prevention market

Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic Phase III Trial Ever to Receive Government Funding

Toronto, Ontario--(Newsfile Corp. - July 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) is today providing a business and corporate update.

Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III

Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) is pleased to announce that the company's CEO Anthony Tennyson will be presenting at two investor conferences this June.

Awakn delivered revenue growth of 24% in the quarter

Seasoned Leader Brings Deep Knowledge of US Biotech Market to Awakn

Study Initiated Following Recent Successful Pilot Study and Patent Filing

Successful Behavioral Addiction Study Supplied Data for Patent

Toronto, Ontario--(Newsfile Corp. - May 24, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that the company's CEO, Anthony Tennyson, will be attending The Investor Hotseat live stream event conducted by Psychedelic Invest. He will be joined in conversation with the host Dustin Robinson, Founder of Iter Investments. The company is inviting investors to join the conversation at The Investor Hotseat which will take place on May 26th 2022 at 4:30PM EST.

Promising Results Merit Larger Study Which Awakn is Initiating

Dr. Dhandayudham Brings Significant Frontline Addiction and Mental Health Medical Leadership Experience to Awakn

Toronto, Ontario--(Newsfile Corp. - May 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn's management team is scheduled to present at the following upcoming May 2022 conferences.

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER...

Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, today is reporting its financial results and business highlights for the three and twelve months ended January 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference to be held on...

Toronto, Ontario--(Newsfile Corp. - April 13, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with a business update on its three fully-operational ketamine-assisted therapy clinics, two in the UK and one in Norway.

Two Chemical Series Identified to Facilitate Lead Optimisation Activities

Toronto, Canada--(Newsfile Corp. - April 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Executive Officer, is scheduled to present at the following upcoming April 2022 investor conferences.

Toronto, Ontario--(Newsfile Corp. - March 22, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, is pleased to announce that they have closed a non-brokered private placement through the issuance of 2,031,250 units (the "Units") at a price of $1.60 per Unit for gross proceeds of $3,250,000 (the "Offering").

Toronto, Ontario--(Newsfile Corp. - March 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Awakn Clinics London has received Care Quality Commission's (CQC) formal approval to begin treatments for addiction and mental health.

Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn's Therapeutics Commercialization Activities in the U.S.

Toronto, Ontario--(Newsfile Corp. - March 9, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Executive Officer, is scheduled to present at the following upcoming March 2022 investor conferences.

Entactogen NCE Series Enhances the Potential to Treat a Broad Range of Addictions

Professor Morgan, Awakn's Head of Ketamine-Assisted Therapy for Addiction, Named One Of The 16 Most Influential Women Shaping The Future Of Psychedelics By Insider

Dr. Sessa Will Discuss the Promise of Psychedelic Medicine in Treating Addiction

Novel Entactogen NCE Series Enhances the Potential for Improved Treatment of Addiction

Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe

Toronto, Ontario--(Newsfile Corp. - January 14, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announces that it has been requested by OTC Markets Group Inc. ("OTC Markets") to issue this statement about certain promotional activity concerning its common stock.

Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events

Groundbreaking psychedelic study will investigate binge eating disorder, compulsive sexual behavior, and internet gaming disorder

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares

Toronto, Ontario--(Newsfile Corp. - December 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, today is reporting its financial results and business highlights for the three and nine months ended October 31, 2021. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Toronto, Ontario--(Newsfile Corp. - December 14, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the appointment of Paul Carter, former Chief Commercial Officer of Gilead Sciences Inc., as an independent member of its Board of Directors, increasing the independent majority on the board. Mr. Carter will be replacing Dr. Benjamin Sessa who has resigned from the Board of Directors, and Dr. Sessa shall continue in his day-to-day role of Co-Founder and Chief Medical Officer.

Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming virtual December investor conferences.

Kate Butler to Be Appointed CFO; Jonathan Held, Current CFO, to Be Appointed Chief Business Officer

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III

World's First Controlled Study to Investigate Ketamine-Assisted Psychotherapy

Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Professor David Nutt, Chief Research Officer of Awakn Life Sciences, and Dr. Ben Sessa, Chief Medical Officer of Awakn Life Sciences, will participate in the Microdose Presents: Wonderland, Miami Conference in-person from Monday, November 8th to Tuesday, November 9th.

This further defines development pathways for next generation of psychedelic medicines to treat addiction

Toronto, Ontario--(Newsfile Corp. - October 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief Executive Officer, Anthony Tennyson, will present a corporate overview at the Benzinga Global Small Cap Conference, which is being held virtually on October 27 - 28, 2021.

The clinic will begin delivering ketamine-assisted psychotherapy treatments in October

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com 

Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, CEO of Awakn Life Sciences, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.

Transaction concludes with the launch of "Awakn Clinics Oslo AS" as part of Awakn Life Sciences Nordic Expansion

This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction

Toronto, Ontario--(Newsfile Corp. - September 20, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in the following upcoming September investor conferences.

Toronto, Ontario--(Newsfile Corp. - September 16, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic medicine to treat addiction, is pleased to announce that it has signed a binding share exchange agreement to acquire a 100% interest in Axonklinikken AS ("Axon"), a leading ketamine-assisted psychotherapy clinic in Norway. As part of the transaction Axon will be renamed 'Awakn Oslo AS', and Axon's majority shareholder Dr. Lowan Stewart will be appointed as Regional Director for the Nordics and Managing Director Awakn Oslo AS.

Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Toronto, Ontario--(Newsfile Corp. - September 9, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in the upcoming H. C. Wainwright conference.

Toronto, Ontario--(Newsfile Corp. - September 2, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that it has received Depository Trust & Clearing Corporation ("DTC") eligibility.

Recruitment Has Commenced for the First-Of-Its-Kind, U.K. - based Study, Led by Renowned Ketamine Researcher

Toronto, Ontario--(Newsfile Corp. - August 12, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified to trade on the OTCQB® Venture Market ("OTCQB") under the ticker symbol "AWKNF" today, Tuesday, August 12, 2021.

Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in Canaccord Genuity's 41st Annual Growth Conference on Tuesday, August 10, 2021.

Toronto, Ontario--(Newsfile Corp. - August 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy center to treat Addiction and other mental health conditions.

Toronto, Ontario--(Newsfile Corp. - July 26, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, today announced approval from the Financial Regulatory Authority ("FINRA") for its shares to commence trading on the OTC Market (the "OTC") in the United States under the symbol "AWKNF" effective today, July 26, 2021. Awakn will continue to trade on the NEO Exchange under its existing symbol "AWKN".

Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board.

Program to Focus on Developing and Delivering New Treatments for Substance and Behavourial Addictions

Awakn's Chief Research Officer Prof. David Nutt Will Chair Both Advisory Boards with Prof. Stephen Husbands, Prof. Harriet De Wit, and Prof. Kevin Fone Joining the Preclinical Advisory Board

Broadening of Intellectual Property Portfolio for These Two NCES Clearly Defines Development Pathway for the Next Generation of Psychedelic Medicines to Treat Addiction

Prof. Nutt Will Drive Progression of a Pipeline of New Psychedelic Medicines, Helping to Define a Clear Development Pathway to Treat Addiction Through Psychedelic Medicines

NEO is excited to announce that Awakn Life Sciences Corp. (“Awakn”), a biotechnology company with

Toronto, Ontario--(Newsfile Corp. - June 23, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) ("Awakn" or the "Company") a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the "NEO") under the symbol "AWKN".

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) -  Further to its press release date May 17, 2021, Awakn Life Sciences Corp. (formerly 1169082 B.C. Ltd.) (the "Company") is pleased to announce that it has completed its reverse takeover transaction (the "Transaction") of Awakn Life Sciences Inc. ("Awakn"), and that the net proceeds from its previously announced brokered private placement of 3,320,220 subscription receipts for aggregate gross proceeds of $8,300,550 (the "Offering") have been released from escrow to Awakn. The Company has also received final approval to list its common shares on the Neo Exchange Inc. ("NEO"), and trading is expected to commence on June 23, 2021 under the stock symbol "AWKN" (CUSIP: 05455W108).